Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>cas 53179-13-8 99% purity pirfenidone powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 53179-13-8 99% purity pirfenidone powder

CAS NO.53179-13-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • Pirfenidone
  • Pirfenidone powder
  • 99% Pirfenidone

Quick Details

  • ProName: cas 53179-13-8 99% purity pirfenidone ...
  • CasNo: 53179-13-8
  • Molecular Formula: C15H22O5
  • Appearance: white
  • Application: Artemisia annua is used as antimalaria...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas 53179-13-8 99% purity pirfenidone  powder 

Product Name:    Pirfenidone
CAS:    53179-13-8
MF:    C12H11NO
MW:    185.22
EINECS:    621-260-7

 

Details

cas 53179-13-8 99% purity pirfenidone  powder 

Product Name:    Pirfenidone
CAS:    53179-13-8
MF:    C12H11NO
MW:    185.22
EINECS:    621-260-7 

Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.